Iden M Amiri, Heran W Gebreyesus, Nathan Grove, Jennifer L Patnaik, Malik Y Kahook, Leonard K Seibold
{"title":"One year clinical outcomes with a novel canaloplasty device in mild to severe open angle glaucoma.","authors":"Iden M Amiri, Heran W Gebreyesus, Nathan Grove, Jennifer L Patnaik, Malik Y Kahook, Leonard K Seibold","doi":"10.18240/ijo.2025.09.08","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the one-year clinical outcomes of a novel canaloplasty device used in combination with cataract extraction (CE) in patients with mild to severe open angle glaucoma (OAG).</p><p><strong>Methods: </strong>This study reviewed patients diagnosed with mild to severe OAG, who underwent canaloplasty with the STREAMLINE® Surgical System combined with CE. The primary outcome was surgical success, defined as achieving ≥20% intraocular pressure (IOP) reduction and/or a reduction of ≥1 glaucoma medication compared to baseline. Secondary outcomes included mean IOP, average number of glaucoma medications, and best-corrected distance visual acuity (BCDVA). Data was collected preoperatively and at multiple postoperative time points up to one year.</p><p><strong>Results: </strong>A total of 68 eyes of 47 patients were included with mean age was 73.1±7.0y and 60% were females. Surgical success at one year was achieved in 68.8% of eyes, with 67.6% success in mild, 80.0% in moderate, and 66.7% in severe OAG cases. IOP was significantly reduced from a baseline of 16.1±0.5 to 14.7±0.4 mm Hg at one year (<i>P</i>=0.0004). The number of medications decreased significantly in all eyes from a baseline of 1.2±0.1 to 0.6±0.1 at one year (<i>P</i><0.0001). When stratified by glaucoma severity, only the mild group experienced a statistically significant decrease from a baseline of 1.1±0.1 to 0.4±0.1 (<i>P</i><0.0001). BCDVA improved significantly from baseline to one year. No sight-threatening complications were reported.</p><p><strong>Conclusion: </strong>Canaloplasty using the STREAMLINE® surgical system combined with CE effectively reduces IOP at one year in mild to severe OAG with minimal complications. IOP lowering efficacy, reduction in IOP lowering medications, and safety in moderate to severe OAG require further study.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"18 9","pages":"1673-1680"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378677/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2025.09.08","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To evaluate the one-year clinical outcomes of a novel canaloplasty device used in combination with cataract extraction (CE) in patients with mild to severe open angle glaucoma (OAG).
Methods: This study reviewed patients diagnosed with mild to severe OAG, who underwent canaloplasty with the STREAMLINE® Surgical System combined with CE. The primary outcome was surgical success, defined as achieving ≥20% intraocular pressure (IOP) reduction and/or a reduction of ≥1 glaucoma medication compared to baseline. Secondary outcomes included mean IOP, average number of glaucoma medications, and best-corrected distance visual acuity (BCDVA). Data was collected preoperatively and at multiple postoperative time points up to one year.
Results: A total of 68 eyes of 47 patients were included with mean age was 73.1±7.0y and 60% were females. Surgical success at one year was achieved in 68.8% of eyes, with 67.6% success in mild, 80.0% in moderate, and 66.7% in severe OAG cases. IOP was significantly reduced from a baseline of 16.1±0.5 to 14.7±0.4 mm Hg at one year (P=0.0004). The number of medications decreased significantly in all eyes from a baseline of 1.2±0.1 to 0.6±0.1 at one year (P<0.0001). When stratified by glaucoma severity, only the mild group experienced a statistically significant decrease from a baseline of 1.1±0.1 to 0.4±0.1 (P<0.0001). BCDVA improved significantly from baseline to one year. No sight-threatening complications were reported.
Conclusion: Canaloplasty using the STREAMLINE® surgical system combined with CE effectively reduces IOP at one year in mild to severe OAG with minimal complications. IOP lowering efficacy, reduction in IOP lowering medications, and safety in moderate to severe OAG require further study.
目的：评价一种新型小管成形术联合白内障摘除（CE）治疗轻至重度开角型青光眼（OAG）患者一年的临床效果。方法：本研究回顾了诊断为轻度至重度OAG的患者，这些患者使用streamlined®手术系统联合CE进行了导管成形术。主要结局是手术成功，定义为与基线相比眼压降低≥20%和/或减少≥1种青光眼药物。次要结果包括平均IOP，平均青光眼药物数量和最佳矫正距离视力（BCDVA）。数据收集于术前和术后多个时间点，时间长达一年。结果：纳入患者47例，68只眼，平均年龄73.1±7.0岁，女性占60%。一年内手术成功率为68.8%，其中轻度、中度和重度OAG分别为67.6%、80.0%和66.7%。一年后，IOP从基线的16.1±0.5降低到14.7±0.4 mm Hg （P=0.0004）。所有眼的用药数量在一年内从基线的1.2±0.1显著下降到0.6±0.1 (ppp结论：使用流线®手术系统联合CE在一年内有效降低轻度至重度OAG患者的IOP，并发症最少。降低IOP的有效性、降低IOP药物的减少以及中度至重度OAG的安全性需要进一步研究。
期刊介绍：
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
